What are Johnson & Johnson's main business segments?

Johnson & Johnson operates through diversified segments, which historically include consumer health, pharmaceuticals, and medical devices/diagnostics. This structure allows for multiple revenue streams and mitigates risks associated with any single market.

What is the company's approach to innovation and growth?

The company places a significant emphasis on Research and Development (R&D), which is critical for developing new products and therapies. This focus is essential for maintaining competitiveness and driving future growth in the dynamic healthcare industry.

How is Johnson & Johnson positioned in terms of financial reporting and corporate governance?

As a large accelerated filer, Johnson & Johnson adheres to stringent SEC reporting requirements, demonstrating a commitment to transparency and investor communication. The company's filing includes standard disclosures regarding its business, risk factors, financial condition, and corporate governance.

Where can investors find more detailed financial information?

Detailed financial information beyond what is presented in the 10-K is available through documents incorporated by reference, such as the company's Annual Report to Shareholders for the fiscal year 2009 and its Proxy Statement for the 2010 annual meeting.

JNJ 10-K FY2010 Annual Report — Revenue, Net Income, EPS

Summary

Johnson & Johnson's 2010 10-K report, filed on February 28, 2010, for the fiscal year ending January 3, 2010, details a company of substantial scale and diversified operations. As a large accelerated filer, JNJ operates across consumer health, pharmaceutical, and medical devices/diagnostics segments, indicating a robust business model with multiple revenue streams. The report emphasizes the company's commitment to research and development, vital for sustained innovation in its highly regulated industries. Investors can take note of JNJ's established market presence and the significant market value of its common stock, as well as its ongoing efforts to maintain compliance and transparency through its extensive filings.

Financial Highlights

31 data points

Beta

Revenue

$61.90B

0.7% Gross Margin

Net Income

$12.27B

0.2% Net Margin

EPS (Diluted)

$4.40

Free Cash Flow

$14.21B

Financial Statements

Beta

Revenue	$61.90B
Cost of Revenue	$18.45B
Gross Profit	$43.45B
SG&A Expenses	$19.80B
Operating Income	$16.58B
Interest Expense	$451.00M
Net Income	$12.27B
EPS (Basic)	$4.45
EPS (Diluted)	$4.40
Shares Outstanding (Basic)	2.76B
Shares Outstanding (Diluted)	2.79B

Key Highlights

1Johnson & Johnson is a large, well-established company operating in the healthcare sector, with its Common Stock registered on the New York Stock Exchange.
2The company operates across multiple segments, including consumer health, pharmaceuticals, and medical devices/diagnostics, offering diversification.
3Significant emphasis is placed on Research and Development (R&D), crucial for innovation and maintaining a competitive edge in its industries.
4The filing indicates a commitment to regulatory compliance and robust corporate governance, as evidenced by its status as a large accelerated filer and detailed reporting.
5The report incorporates by reference portions of the company's Annual Report to Shareholders and Proxy Statement, providing further detailed financial and operational information.
6JNJ maintains a significant market capitalization, with a reported aggregate market value of approximately $156 billion in common stock held by non-affiliates as of the last business day of the second fiscal quarter.

JOHNSON & JOHNSON Annual Report, Year Ended Jan 3, 2010

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions